
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
In celebration of the long weekend, enjoy these selected psychiatry comics by cartoonist Jonny Hawkins.




